We recently demonstrated that nonvisual arrestins interact via a C-terminal binding domain with clathrin and function as adaptor proteins to promote ␤ 2 -adrenergic receptor (␤ 2 AR) internalization. Here, we investigated the potential utility of a mini-gene expressing the clathrin-binding domain of ␤-arrestin (␤-arrestin (319 -418)) to function as a dominant-negative with respect to ␤ 2 AR internalization and compared its properties with those of ␤-arrestin and ␤-arrestin-V53D, a previously reported dominant-negative mutant. In vitro studies demonstrated that ␤-arrestin-V53D bound better to clathrin than ␤-arrestin but was significantly impaired in its interaction with phosphorylated G protein-coupled receptors. In contrast, whereas ␤-arrestin (319 -418) also bound well to clathrin it completely lacked receptor binding activity. When coexpressed with the ␤ 2 AR in HEK293 cells, ␤-arrestin (319 -418) effectively inhibited agonist-promoted receptor internalization, whereas ␤-arrestin-V53D was only modestly effective. However, both constructs significantly inhibited the stimulation of ␤ 2 AR internalization by ␤-arrestin in COS-1 cells. Interestingly, immunofluorescence microscopy analysis reveals that both ␤-arrestin (319 -418) and ␤-arrestin-V53D are constitutively localized in clathrincoated pits in COS-1 cells. These results indicate the potential usefulness of ␤-arrestin (319 -418) to effectively block arrestin-clathrin interaction in cells and suggest that this construct may prove useful in further defining the mechanisms involved in G protein-coupled receptor trafficking.
latter step that sterically inhibits G protein binding to the agonist-activated GPR (2, 3). There are currently four known mammalian arrestins: two visual arrestins, arrestin and cone arrestin (4, 5) , and two nonvisual arrestins, ␤-arrestin and arrestin3 (6, 7) . By virtue of their restricted localization predominantly to retinal tissue (4 -6) and supported by in vitro binding studies (8, 9) , it appears that the visual arrestins specifically regulate photoreceptor signaling. In contrast, the ubiquitous expression of ␤-arrestin and arrestin3 (6, 10) , as well as in vitro binding studies (8, 9) , strongly suggest that these arrestins regulate a wide variety of GPRs. Indeed, intact cell studies have demonstrated a role for the nonvisual arrestins in regulation of the ␤ 2 -adrenergic (11), ␤ 1 -adrenergic (12) , ␣ 1B -adrenergic (13) , and odorant (14) receptors.
Another level of regulation of GPRs is their internalization or sequestration following agonist exposure. Agonist-induced internalization of GPRs occurs subsequent to the rapid agonistinduced desensitization mediated by GRKs and arrestins. Recent studies have directly demonstrated a role for GRKs in mediating internalization of GPRs. Coexpression of GRK2 with either the m2 muscarinic acetylcholine receptor (m2AChR) or a sequestration-defective ␤ 2 AR (␤ 2 AR-Y326A) resulted in enhanced internalization of these receptors, whereas coexpression with dominant-negative GRK2 attenuated receptor internalization (15, 16) . It is evident that GRKs mediate the enhanced internalization of GPRs through arrestins. Coexpression of ␤-arrestin or arrestin3 with ␤ 2 AR-Y326A rescued the sequestration-defective phenotype of this mutant (17) . Moreover, coexpression of mutant forms of ␤-arrestin or arrestin3 (containing a single Val to Asp mutation in the far N terminus) with the ␤ 2 AR inhibited internalization, whereas coexpression of these mutants with GRK2 and ␤ 2 AR-Y326A prevented GRK2-promoted receptor sequestration (17) .
We recently described a potential molecular mechanism of nonvisual arrestin-promoted GPR internalization (18) . We observed that ␤-arrestin and arrestin3 but not visual arrestin interact specifically, stoichiometrically, and with high affinity with clathrin, the major protein component of coated pits. Importantly, the in vitro interaction between ␤-arrestin and clathrin was substantiated by the immunofluorescence colocalization of ␤-arrestin, clathrin, and surface ␤ 2 AR following agonist activation in intact cells. Thus, by virtue of its ability to bind to both the receptor and clathrin, ␤-arrestin uncouples the ␤ 2 AR from G protein and then targets it for internalization through clathrin-coated pits. We further demonstrated that the predominant clathrin-binding domain in nonvisual arrestins is localized to a domain (amino acids 367-385 in arrestin3) that contains several hydrophobic and acidic residues critical for clathrin binding (19) and that the clathrin terminal domain contains a complementary sequence that is involved in arrestin binding (20) . In light of these findings it is interesting that nonvisual arrestins containing a single mutation in their N terminus apparently function as dominant-negative proteins with respect to ␤ 2 AR sequestration (17) . In this report, we biochemically characterize the Val to Asp mutant of ␤-arrestin (␤-arrestin-V53D) as well as a ␤-arrestin clathrin-binding domain construct (␤-arrestin (319 -418)) and assess the potential utility of these proteins to disrupt ␤ 2 AR internalization.
EXPERIMENTAL PROCEDURES

Materials-[
3 H]Leucine and [␥-32 P]ATP were purchased from NEN Life Science Products. All restriction enzymes were purchased from Boehringer Mannheim. Sepharose 2B and all other chemicals were purchased from Sigma. Rabbit reticulocyte lysate was purchased from Promega. SP6 polymerase was prepared as described previously (21) . Reagents were generously provided by Drs. S. Schmid and H. Damke (dynamin-K44A), V. Gurevich (purified bovine ␤-arrestin-V53D), M. Hosey (purified m2AChR), S. Ferguson and M. Caron (rat ␤-arrestin-V53D), B. Kobilka (Flag-tagged ␤ 2 AR), P. Goldsmith and A. Spiegel (␤-arrestin antibodies), and R. K. Crouch (11-cis-retinal) .
Generation of Expression Constructs-␤-Arrestin-V53D was generated by amplifying a ϳ206-base pair fragment of bovine ␤-arrestin by polymerase chain reaction using a sense primer containing a single mutation (underlined) (5Ј-cttgtggatccggagtatctcaaggagaggagagactatg-3Ј) and an antisense primer (5Ј-ggtaggcatgctcgcccagcttat-3Ј). The resulting product was digested with BamHI and SphI and then ligated into BamHI/SphI digested SP6-modified pBluescript KS containing ␤-arrestin. ␤-Arrestin and ␤-arrestin-V53D cDNAs were then excised with NotI and HindIII, blunted with Klenow, and ligated into pcDNA3 (Invitrogen) that was digested with EcoRV and treated with phosphatase. Orientation was confirmed by restriction analysis. ␤-Arrestin (319 -418) was generated by polymerase chain reaction amplification of bovine ␤-arrestin using sense (5Ј-caataagcttaccatggtttcctacaaagtgaaagtg-3Ј) and antisense (5Ј-agatggatccctatctgtcgttgagccg-3Ј) primers. The sense primer contained a Kozak consensus sequence for initiation (underlined) preceding residue 319 in ␤-arrestin. The resulting product was digested with HindIII and BamHI, purified, and then ligated into HindIII/BamHI-digested pcDNA3. In all of these studies we used the 418-amino acid-long variant of ␤-arrestin (10). All sequences were confirmed by DNA sequencing (Sidney Kimmel Nucleic Acid Facility, Thomas Jefferson University).
Flag-tagged ␤ 2 AR in pcDNA3 was generated by digesting pBCFlag␤ 2 AR with SalI followed by Klenow to blunt the 3Ј end. The insert was excised with HindIII and the ϳ2-kilobase fragment was ligated into HindIII/EcoRV-digested pcDNA3. Dynamin-K44A (clone pUHD10 -3) was excised by BamHI digestion, purified, and then ligated into BamHI-digested and phosphatase-treated pcDNA3.
In Vitro Transcription and Translation of ␤-Arrestin ConstructscDNAs were linearized with HindIII or EcoRV (␤-arrestin (319 -418)) and purified on a 1% agarose gel. In vitro transcription and translation were performed as described previously (22) . The specific activities and concentrations of in vitro translated proteins were calculated to be ϳ500 -1700 dpm/fmol and ϳ10 -55 nM, respectively.
Preparation of Clathrin Cages and Cage Binding Assay-The preparation of clathrin and clathrin cages (23) and the cage binding assay (18) have been previously described. Briefly, in vitro translated radiolabeled arrestins (0.5 nM) were incubated with or without clathrin cages for 30 min at 22°C in a total volume of 50 l in 100 mM Na-MES, pH 6.8, 1 mM dithiothreitol, and 1 g/ml each of leupeptin, pepstatin, and antipain. Samples were cooled on ice, loaded onto a 75-l 0.2 M sucrose cushion in 100 mM Na-MES, pH 6.8, and centrifuged for 5 min at 100,000 rpm at 4°C in a TLA100.1 rotor. Pellets were resuspended in 20 l of SDS sample buffer, heated at 100°C for 5 min, and electrophoresed on 10% SDS-polyacrylamide gels. Gels were stained with Coomassie Blue, destained, enhanced with 20% 2,5-diphenyloxazole in glacial acetic acid, dried, and autoradiographed. Quantitation was carried out by PhosphorImager analysis (Molecular Dynamics). Specific binding was determined by comparing the intensity of bands in the experimental samples to the intensity of standards loaded on the same gel. Nonspecific sedimentation (ϳ4, ϳ8, and ϳ5-10% of total input for ␤-arrestin, ␤-arrestin-V53D, and ␤-arrestin (319 -418), respectively) was assessed in the absence of clathrin cages and subtracted from all experimental values.
Rhodopsin Preparation and Rhodopsin Binding Assay-Ureatreated rod outer segment membranes were prepared, phosphorylated with GRK2 to a stoichiometry of ϳ2.7 mol/mol, and regenerated with 11-cis-retinal as described (24) . Arrestin binding to phosphorylated agonist-activated receptors was carried out as described (9) . Briefly, in vitro translated radiolabeled arrestins (0.5 nM) were incubated for 5 min at 37°C with phosphorylated rhodopsin or m2AChR in a total volume of 50 l in 50 mM Tris-HCl, pH 7.5, 0.5 mM MgCl 2 , 100 mM potassium acetate, 1.5 mM dithiothreitol. Samples were then placed on ice, and receptor-bound arrestins were separated from unbound arrestins by Sepharose 2B column chromatography. Nonspecific binding was assessed in the absence of receptor (ϳ1.0, ϳ0.7, and ϳ1.6 fmol for ␤-arrestin, ␤-arrestin-V53D, and ␤-arrestin (319 -418), respectively).
Internalization Experiments in HEK293 and COS-1 Cells-HEK293 and COS-1 cells were grown in T75 flasks at 37°C in a humidified atmosphere containing 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 g/ml streptomycin (complete medium). The cells were grown to ϳ80 -90% confluence and then transfected with the various constructs using LipofectAMINE according to the manufacturer's instructions (Life Technologies, Inc.). Briefly, DNAs were incubated with 95 (HEK293 cells) or 65 (COS-1 cells) l of LipofectAMINE in 5 ml of DMEM for 30 min at 22°C. 5 ml of DMEM was then combined with the DNA/LipofectAMINE and added to a T75 flask of DMEM-rinsed cells. After 5 h at 37°C, the DNA-containing medium was replaced with complete medium.
Transfected cells were harvested by trypsinization ϳ48 h after transfection, washed twice with cold PBS and resuspended in 1.5 ml of cold PBS containing 0.1 mM ascorbic acid. Cells (0.5 ml) were incubated with or without 10 M (Ϫ)-isoproterenol at 37°C for various times, washed twice with 50 ml of cold PBS, and resuspended in 1.5 ml of cold PBS. Cell surface receptors were measured directly by incubation with ϳ10 nM [
3 H]CGP-12177 (Amersham) for 3 h at 14°C with nonspecific binding assessed in the presence of 10 M (Ϫ)-alprenolol. Bound ligands were separated on a Brandel cell harvester.
To assess expression of the various ␤-arrestin constructs, 0.1 ml of the resuspended cells were pelleted by centrifugation, resuspended in 0.2 ml of cold lysis buffer (20 mM Hepes, pH 7.2, 10 mM EDTA, 0.2 M NaCl, 1% Triton X-100, 0.1 mg/ml benzamidine, 1 mM phenylmethylsulfonyl fluoride), and then lysed by freeze/thaw and vortexing. Following centrifugation, supernatant protein was electrophoresed on a 10% SDS-polyacrylamide gel, transferred to nitrocellulose, and then immunoblotted using a 1:2000 dilution of a ␤-arrestin-specific rabbit polyclonal antibody as described previously (19) . The blots were washed, incubated with horseradish peroxidase-conjugated secondary antibody, and then visualized by chemiluminescence using ECL (Amersham). Protein concentrations were determined by Bio-Rad assay using bovine serum albumin as a standard.
Immunofluorescence and Confocal Microscopy-Cells were processed for immunofluorescence analysis as described previously (25) . Cell stimulation was performed by incubating the cells in Hepes-DMEM containing 10 M (Ϫ)-isoproterenol for 10 min at 37°C. Following fixation and permeabilization, clathrin was detected using either rabbit polyclonal antiserum 27004 (1:100 dilution) (26) or mouse monoclonal antibody X22 (20 g/ml), and ␤-arrestin was detected using a rabbit affinity-purified antibody raised against a C-terminal 16-amino acid peptide (1:250 dilution) (10) . Primary antisera were detected with either fluorescein-conjugated or rhodamine-lissamine-conjugated donkey anti-rabbit IgG or donkey anti-mouse IgG secondary antibodies (each 1:100 dilutions), preadsorbed to minimize interspecies cross-reactivity (Jackson Immuno Research).
Confocal microscopy was performed on a Bio-Rad MRC-600 laser scanning confocal microscope (Hemmelholsteadt) attached to a Zeiss Axiovert 100 microscope using a Zeiss Plan-Apo 63 ϫ 1.40 NA oil immersion lens. Cells expressing the lowest levels of transfected proteins but clearly above those of nonexpressing counterparts in the same specimens were chosen for view. Images of each fluorescent signal were collected sequentially in the photon counting mode using single line excitation.
RESULTS AND DISCUSSION
Recent evidence has indicated that nonvisual arrestins function as clathrin adaptor proteins (18) , a function that explains their ability to promote GPR internalization (17, 18) . Further evidence that nonvisual arrestins are directly involved in GPR internalization comes from the functional characterization of mutant forms of these proteins (␤-arrestin-V53D and arrestin3-V54D). These mutants were reported to significantly inhibit the sequestration of coexpressed wild-type ␤ 2 AR and to block the ability of GRK2 to rescue the sequestration-defective phenotype of a mutant ␤ 2 AR containing a Y326A mutation (17) .
Thus, these mutants were referred to as "dominant-negative" proteins with respect to inhibiting GPR internalization.
To shed light on the ability of ␤-arrestin-V53D to function as a dominant-negative mutant, we measured its binding to both clathrin and GPRs because altered interaction with either component might contribute to its functional phenotype. In vitro translated ␤-arrestin-V53D and ␤-arrestin were incubated with increasing concentrations of clathrin cages, and following sedimentation, bound arrestins were determined by polyacrylamide gel electrophoresis, autoradiography, and densitometry analysis. As demonstrated in Fig. 1A , ␤-arrestin-V53D is not defective in clathrin binding and, in fact, appears to bind better to clathrin than ␤-arrestin. Moreover, under conditions in which ␤-arrestin dissociates significantly (Ͼ50%) from clathrin, we observe minimal (Ͻ10%) ␤-arrestin-V53D dissociation from clathrin (data not shown). Furthermore, purified recombinant ␤-arrestin-V53D expressed in Escherichia coli binds to clathrin cages with high affinity (data not shown).
The lack of a detrimental effect on clathrin binding is consistent with the mutation site in ␤-arrestin-V53D being located in a region not directly involved in clathrin binding (19) . The apparent ability of ␤-arrestin-V53D to interact better with clathrin than ␤-arrestin may be explained in light of the proposed role of the far N terminus of arrestins in interacting with the far C terminus to regulate the overall conformation of arrestins (9, 24, 27) . It is conceivable that this mutation alters this interaction, thus rendering the far C terminus containing the clathrin-binding domain more accessible. A possible conformational change in ␤-arrestin-V53D, however, is likely to be modest since trypsin proteolysis patterns of ␤-arrestin and ␤-arrestin-V53D were very similar (data not shown).
We next assessed the GPR binding properties of ␤-arrestin-V53D. Incubation of in vitro translated radiolabeled ␤-arrestin and ␤-arrestin-V53D with phosphorylated rod outer segment membranes demonstrates that ␤-arrestin-V53D is impaired in interacting with phosphorylated light-activated rhodopsin (Fig.  1B) . Moreover, ␤-arrestin-V53D binding to phosphorylated agonist-activated m2AChR was also significantly impaired (data not shown). The defect in GPR binding of ␤-arrestin-V53D is consistent with the site of the mutation being located close to the primary GPR-binding regions in arrestins (8, 9, 22, 24) . Thus, it seems that this mutation either directly or indirectly interferes with the primary GPR-binding domains in ␤-arrestin.
The ability of ␤-arrestin-V53D to interact well with clathrin together with its decreased ability to interact with phosphorylated agonist-activated GPRs suggest that this mutant would be defective in promoting GPR internalization and may function as a dominant-negative protein as previously reported (17) . However, we reasoned that a construct that expresses only the clathrin-binding determinants of ␤-arrestin (i.e. no receptorbinding determinants) might function as a more effective dominant-negative for inhibiting arrestin-promoted receptor internalization. Given our localization of the clathrin-binding domain in nonvisual arrestins to the far C terminus (18, 19) and localization of the primary receptor-binding determinants to the N-terminal half (8, 9, 22, 24), we devised a construct expressing the C-terminal 100 amino acids of ␤-arrestin (␤-arrestin (319 -418)). In vitro translated ␤-arrestin (319 -418) binds specifically to clathrin cages, although its extent of binding appears modestly reduced ( Fig. 2A) . However, the decreased extent of binding of ␤-arrestin (319 -418) to clathrin compared with ␤-arrestin is likely due to differences in the relative stability of the in vitro translated proteins because a GST fusion protein containing the C-terminal 100 amino acids of ␤-arrestin bound to clathrin cages with a comparable affinity and extent as ␤-arrestin (data not shown). Importantly, ␤-arrestin (319 -418) demonstrates no significant binding to phosphorylated light-activated rhodopsin (Fig. 2B) . Moreover, GST-␤-arrestin (319 -418) and a corresponding construct of arrestin3 (GST-arrestin3 (318 -409)), which was shown to interact very well with clathrin (19), also did not interact with phosphorylated light-activated rhodopsin (data not shown).
We next assessed the ability of ␤-arrestin-V53D and ␤-arrestin (319 -418) to inhibit agonist-induced GPR internalization. HEK293 cells were initially chosen because they demonstrate a high level of agonist-induced ␤ 2 AR internalization mediated by endogenous arrestins (17) . HEK293 cells were transfected with ␤ 2 AR alone or together with different ␤-arrestin constructs or with a dynamin dominant-negative mutant (dynamin-K44A) that is an effective inhibitor of clathrin-mediated endocytosis (28) . ␤-Arrestin, ␤-arrestin-V53D, and ␤-arrestin (319 -418) were all expressed at ϳ20 -35-fold above endogenous nonvisual arrestin levels (Fig. 3A) . We next measured the effect of these proteins on cell surface receptor loss induced by 15 min of treatment with isoproterenol. Although ␤-arrestin-V53D demonstrates a modest effect on ␤ 2 AR internalization, ␤-arrestin (319 -418) inhibits ␤ 2 AR internalization almost as well as dynamin-K44A (Fig. 3B) . In addition, rat ␤-arrestin-V53D and bovine arrestin3-V54D were also ineffective dominant-negative proteins when expressed in HEK293 cells (data not shown). These findings demonstrate that ␤-arrestin (319 -418) is a more effective inhibitor of ␤ 2 AR internalization than ␤-arrestin-V53D.
Interestingly, immunofluorescence analyses of transfected HEK293 cells demonstrated that ␤-arrestin (319 -418) is localized in clathrin-coated pits in the absence of agonist, whereas ␤-arrestin-V53D is diffusely distributed (data not shown), indicating that the ability of ␤-arrestin (319 -418) to inhibit ␤ 2 AR internalization may lie in its apparent effectiveness in blocking endogenous clathrin-binding sites. Moreover, the inability of ␤-arrestin to stimulate ␤ 2 AR internalization in HEK293 cells (Fig. 3B and Ref. 17) , despite significant overexpression (Fig.  3A) , is consistent with the apparent inability of ␤-arrestin to colocalize with clathrin-coated pits in an agonist-dependent fashion in HEK293 cells (data not shown), in contrast to the dramatic agonist-dependent colocalization of ␤-arrestin with clathrin-coated pits observed in COS-1 cells (18) .
We next investigated the ability of ␤-arrestin-V53D and ␤-arrestin (319 -418) to modulate receptor internalization in COS-1 cells. COS-1 cells demonstrate a lower level of agonistinduced GPR internalization in the absence of arrestin or GRK coexpression than HEK293 (29) . Thus, we assessed the effect of ␤-arrestin-V53D and ␤-arrestin (319 -418) expression on ␤-arrestin-promoted ␤ 2 AR internalization in these cells. Coexpression of the ␤ 2 AR with ␤-arrestin results in a significant enhancement of ␤ 2 AR internalization, whereas coexpression with ␤-arrestin (319 -418) has no effect on the basal agonist-induced internalization (Fig. 4) . Interestingly, coexpression of either ␤-arrestin-V53D or ␤-arrestin (319 -418) significantly inhibited the effect of ␤-arrestin. Importantly, ␤-arrestin (319 -418) and ␤-arrestin-V53D did not have any apparent effect on internalization of the transferrin receptor (data not shown), indicating that expression of either of these constructs does not inhibit all clathrin-mediated endocytotic processes.
Because both ␤-arrestin-V53D and ␤-arrestin (319 -418) inhibit the ability of ␤-arrestin to promote ␤ 2 AR internalization in COS-1 cells, we next performed immunofluorescence analyses in these cells. As demonstrated in Fig. 5 , we observe localization of both ␤-arrestin-V53D and ␤-arrestin (319 -418) in clathrin-coated pits in the absence of receptor activation. This is in contrast to the localization of ␤-arrestin in clathrin-coated pits only in the presence of the agonist-activated receptor (Fig.  5 and Ref. 18) . Thus, the ability of ␤-arrestin-V53D and ␤-arrestin (319 -418) to modulate arrestin-promoted ␤ 2 AR inter- were harvested ϳ48 h after transfection. Cells were lysed, and 15 g of protein were analyzed by immunoblotting using a ␤-arrestin-specific antibody as described under "Experimental Procedures." This gel is representative of four each with similar results. B, effect of ␤-arrestin-V53D and ␤-arrestin (319 -418) on ␤ 2 AR sequestration. HEK293 cells transfected with 5 g of pcDNA3-␤ 2 AR alone or together with 5 g of pcDNA3-␤-arrestin, pcDNA3-␤-arrestin-V53D, pcDNA3-␤-arrestin (319 -418), or pcDNA3-dynamin-K44A were harvested ϳ48 h after transfection. The cells were incubated with 10 M (Ϫ)-isoproterenol at 37°C for 15 min, washed extensively, resuspended, and then analyzed for cell surface ␤ 2 AR as described under "Experimental Procedures." ␤ 2 AR expression levels were ϳ1.9, ϳ1.7, ϳ1.9, ϳ1.8, and ϳ2.0 pmol/mg in ␤ 2 AR alone and ␤-arrestin-, ␤-arrestin-V53D-, ␤-arrestin (319 -418)-, and dynamin-K44A-cotransfected HEK293 cells, respectively. The data represent the means Ϯ S.E. of four independent experiments.
nalization in COS-1 cells may lie in their ability to block endogenous clathrin-binding sites. The constitutive localization of ␤-arrestin-V53D in coated pits is consistent with the good clathrin binding exhibited by this mutant (Fig. 1A) and again suggests that the clathrin-binding domain is more accessible in ␤-arrestin-V53D than in ␤-arrestin. Moreover, because ␤-arrestin is only colocalized with coated pits in the presence of the agonist-activated ␤ 2 AR, it is tempting to speculate that upon binding to the phosphorylated agonist-activated GPR, ␤-arrestin undergoes a conformational change that renders the clathrin-binding site more accessible and that this change is partially mimicked by the ␤-arrestin-V53D mutant. The constitutive localization of ␤-arrestin (319 -418) in coated pits in both COS-1 and HEK293 cells (Fig. 5 and data not shown) is consistent with the strong clathrin binding properties of ␤-arrestin (319 -418) ( Fig. 2A) , GST-␤-arrestin (319 -418) (data not shown), and GST-arrestin3 (318 -409) (19) . Moreover, the localization of ␤-arrestin (319 -418) in coated pits also suggests that its clathrin-binding domain is more accessible than in ␤-arrestin. Finally, the apparent differences in the localization of ␤-arrestin-V53D in COS-1 versus HEK293 cells (Fig. 5 and data not shown), as well as the differences in trafficking of ␤-arrestin in COS-1 versus HEK293 cells (Ref. 18 and data not shown), suggest that multiple mechanisms may be involved in agonist-induced trafficking of GPRs and that they may vary in different cells. Investigation into these possible differences are currently underway.
In summary, we have biochemically characterized a C-terminal 100-amino acid construct of ␤-arrestin and an N-terminal Val to Asp mutant of ␤-arrestin with respect to their ability to interact with both receptors and clathrin and to disrupt agonist-induced GPR internalization in intact cells. We observed that ␤-arrestin-V53D binds well to clathrin but weakly to phosphorylated agonist-activated GPRs. Moreover, although ␤-arrestin-V53D inhibited the agonist-induced ␤ 2 AR internal- FIG. 5 . Immunofluorescence microscopy of transiently transfected COS-1 cells. COS-1 cells were transiently transfected with Flag-tagged ␤ 2 AR and wild-type ␤-arrestin (wt) in the absence (Ϫ) or the presence (ϩ) of agonist or in the absence of agonist with ␤-arrestin-V53D (V53D) or ␤-arrestin (319 -418) (319 -418). Cells were fixed and immunostained using a ␤-arrestin-specific antibody (left panels) and clathrin-specific antibody (right panels) as described under "Experimental Procedures." In the absence of stimulus, ␤-arrestin distribution is largely diffuse, whereas ␤-arrestin-V53D and ␤-arrestin (319 -418) appear punctate and are significantly colocalized with clathrin in coated pits (see enlarged lower panels). After a 10-min incubation with isoproterenol, wild-type ␤-arrestin also appears punctate and colocalized with clathrin. In each pair of images, the bar corresponds to 10 m. ization promoted by exogenous ␤-arrestin in COS-1 cells, it was found to be only modestly effective in HEK293 cells. In contrast, ␤-arrestin (319 -418), a construct that binds well to clathrin and completely lacks GPR binding activity, effectively inhibited agonist-induced ␤ 2 AR internalization in both COS-1 and HEK293 cells. Finally, immunofluorescence analyses demonstrated that although ␤-arrestin (319 -418) is constitutively localized in clathrin-coated pits in both COS-1 and HEK293 cells, ␤-arrestin-V53D is constitutively localized in coated pits only in COS-1 cells. These results demonstrate that ␤-arrestin (319 -418) effectively blocks the arrestin-clathrin interaction in different cells and indicate the potential usefulness of this construct as a specific tool to investigate the agonist-induced trafficking of other GPRs.
